Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug

Published on 16 Apr 2024 on Zacks via Yahoo Finance

Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug

Neumora Therapeutics, Inc. NMRA announced that the FDA has placed a clinical hold on the phase I study, which evaluated NMRA-266, its positive allosteric modulator (PAM) of the M4 muscarinic receptor, for treating some types of neuropsychiatric disorders.

The regulatory body placed the clinical hold after pre-clinical data showed convulsions in rabbits following treatment with NMRA-266.

Read the rest of the article

NASDAQ.ANIP price evolution

NASDAQ.ADMA price evolution

NASDAQ.LGND price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down

Editas Medicine, Inc. EDIT incurred a loss of 76 cents per share in the first quarter of 2024, wi...

Zacks via Yahoo Finance 9 May 2024

Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates

Halozyme Therapeutics, Inc. HALO reported first-quarter 2024 adjusted earnings of 79 cents per sh...

Zacks via Yahoo Finance 8 May 2024

Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates

Ligand Pharmaceuticals Incorporated LGND reported core adjusted diluted net income per share of $...

Zacks via Yahoo Finance 8 May 2024

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript May 7, 2024 Li...

Insider Monkey via Yahoo Finance 8 May 2024

Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates

Axsome Therapeutics, Inc. AXSM reported an adjusted loss of $1.00 per share for the first quarter...

Zacks via Yahoo Finance 8 May 2024

Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion

Roche RHHBY announced that the FDA has approved a label expansion of its lung cancer drug, Alecen...

Zacks via Yahoo Finance 19 Apr 2024

Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up

Vanda Pharmaceuticals Inc. VNDA announced that its board of directors has unanimously rejected a ...

Zacks via Yahoo Finance 18 Apr 2024

Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug

Neumora Therapeutics, Inc. NMRA announced that the FDA has placed a clinical hold on the phase I ...

Zacks via Yahoo Finance 16 Apr 2024

Corcept (CORT) Completes Enrollment in Phase II ALS Study

Corcept Therapeutics Incorporated CORT announced that it has completed enrollment in the phase II...

Zacks via Yahoo Finance 16 Apr 2024

Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors

Shares of cancer-biotech Janux Therapeutics, Inc. JANX have surged close to 50% in the past week,...

Zacks via Yahoo Finance 15 Apr 2024

News

Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug

NASDAQ.ANIP price evolution

NASDAQ.ADMA price evolution

NASDAQ.LGND price evolution

Want to become a better investor?